Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy.

Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress

Photo by National Cancer Institute on Unsplash

As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc. (NYSE:NUVB).

With over 90% of analysts covering Nuvation Bio Inc. (NYSE:NUVB) maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%.

As investors focus on IBTROZI’s commercial launch and the company’s growing oncology pipeline, sentiment remains positive. Moreover, analyst confidence has been bolstered by Nuvation Bio Inc. (NYSE:NUVB)’s early commercialization progress.

Consequently, RBC Capital analysts increased the firm’s price target from $12.00 to $13.00 and reaffirmed their “Outperform” rating for Nuvation Bio Inc. (NYSE:NUVB) on March 3, 2026. They highlighted the long-term potential across the company’s oncology pipeline and the strong physician adoption of IBTROZI.

According to Nuvation Bio Inc.’s (NYSE:NUVB) March 2, 2026, fourth-quarter earnings release, IBTROZI generated $15.70 million in net product revenue in Q4, with 216 new patients starting treatment. A $25.00 million milestone payment from Nippon Kayaku was the main driver of the company’s $26.20 million collaboration and license revenue, helping its cash and equivalents reach $529.20 million as of December 31, 2025. Nuvation Bio reported a net loss of $36.6 million, or $(0.11) per share. The net loss for the comparable period in 2024 was $49.4 million, or $0.15 per share.

Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.